Stigmasterol and Osteoporosis
Author Information
Author(s): Zhao Qiangqiang, Chen Xingling, Mai Bin, Che Feihong, Zhang Zhen, Kang Pan, Hou Chengyu, Lu Lu, Xu Liangliang
Primary Institution: Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
Hypothesis
This study aims to explore the potential mechanisms by which stigmasterol inhibits osteoclasts and assess its impact on osteoporosis.
Conclusion
Stigmasterol effectively inhibits the phosphorylation of the p65 protein in the NF-κB pathway and influences the MAPK signaling pathway, thereby reducing osteoclast formation and preserving bone mass.
Supporting Evidence
- Stigmasterol significantly inhibited osteoclast activity in vitro.
- STG treatment reduced osteoclast numbers and spreading areas.
- Western blot analysis showed that STG inhibited the phosphorylation of the p65 subunit in the NF-κB pathway.
- Micro-CT analysis indicated significant protective effects of STG against bone loss.
- Histopathological staining confirmed STG’s efficacy in reducing bone surface area and volume loss.
Takeaway
Stigmasterol is a plant compound that helps protect bones by stopping certain cells from breaking them down, which is especially important for people with osteoporosis.
Methodology
The study used in vitro and in vivo experiments, including osteoclast differentiation assays and an ovariectomy model to assess the effects of stigmasterol on bone mass.
Participant Demographics
32 specific pathogen-free C57BL/6J female mice, aged 7 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website